BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Risen (Suzhou) Pharma Tech Co.\, Ltd. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Risen (Suzhou) Pharma Tech Co.\, 
 Ltd.'s drugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06208410-9068@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20270226
DTEND;VALUE=DATE:20270227
SUMMARY:JS105: Phase 1/2 readout est. (NCT06208410)
DESCRIPTION:JS105\, phase 1/2.\nStudy: A Clinical Study of JS105 in Combina
 tion With Other Anti-tumor Therapies in Patients With Solid Tumors\nEstima
 ted primary completion: 26 February 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/js105#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06208410
URL:https://assetmemo.bio/drug/js105#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07579884-776@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:RP902: Phase 2 readout est. (NCT07579884)
DESCRIPTION:RP902\, phase 2.\nStudy: To Evaluate the Safety and Efficacy of
  RP902 Tablets\nEstimated primary completion: May 2029. This is a Clinical
 Trials.gov estimate\, not a confirmed readout date\, and it can move.\nDru
 g page: https://assetmemo.bio/drug/rp902#upcoming-events\nRegistry record:
  https://clinicaltrials.gov/study/NCT07579884
URL:https://assetmemo.bio/drug/rp902#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07207070-9068@assetmemo.bio
DTSTAMP:20261121T005925Z
DTSTART;VALUE=DATE:20290531
DTEND;VALUE=DATE:20290601
SUMMARY:JS105: Phase 3 readout est. (NCT07207070)
DESCRIPTION:JS105\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nStudy: A
  Randomised\, Open-label\, Multicentre Phase III Clinical Study to Evaluat
 e the Efficacy and Safety of JS105 Combined With Dalpiciclib and Fulvestra
 nt Compared With Dalpiciclib and Fulvestrant in Patients With PIK3CA-mutat
 ed\, HR-positive\, HER2-negative Recurrent or Metastatic Breast Cancer.\nE
 stimated primary completion: 31 May 2029. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/js105#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT07207070
URL:https://assetmemo.bio/drug/js105#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
